New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

The burdens that monthly or every-other-month injections in the eye impose on patients with retinal diseases are well-known to be barriers to care for many people with these conditions. Making ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Researchers at Science Tokyo developed an mRNA vaccine that suppressed abnormal retinal blood vessel growth in mouse models. The vaccine can be administered intramuscularly and showed effectiveness ...

Continuous use of tear substitutes significantly improved dry eye symptoms in patients with neovascular age-related macular degeneration (AMD) who received frequent eye injections, whereas ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 results due in 2025. The wet AMD market is lucrative, but the challenge lies in ...

Age-Related Macular Degeneration (AMD) is the biggest cause of sight loss in the UK, affecting around 700,000 people. As ...

Regenxbio and AbbVie have taken a small step toward in-office administration of their eye disease gene therapy candidate. Interim phase 2 data suggest the prospect can be given safely at the doctor’s ...

Over time, natural changes can affect your vision, making everyday tasks more challenging. Here are some of the most common age-related eye issues and what you can do about them. Your lenses, located ...